Statins and fibrates as the treatment of nonproliferative diabetic retinopathy in type 2 diabetes mellitus; [Statine und Fibrate als Therapie der nichtproliferativen diabetischen Retinopathie bei Typ-2-Diabetes]

被引:3
|
作者
Ilyina Y. [1 ]
Bezditko P. [2 ]
Samer Mohamed A. [2 ]
Zavoloka O. [2 ]
Zubkova D. [2 ]
机构
[1] Department of Ophthalmology, Kharkiv National Medical University, Kharkiv
[2] Science av. 4, Kharkiv
关键词
Fibrates; Glycosylated hemoglobin; Lipids; Nonproliferative diabetic retinopathy; Statins;
D O I
10.1007/s00717-016-0300-2
中图分类号
学科分类号
摘要
Background: Diabetic retinopathy is the result of microvascular retinal changes. Hyperglycemia-induced intramural pericyte death and thickening of the basement membrane lead to incompetence of the vascular walls. The purpose was to improve medication for nonproliferative diabetic retinopathy in patients with type 2 diabetes mellitus using statins and fibrates. Methods: A total of 47 patients (94 eyes) with nonproliferative diabetic retinopathy (moderate stage) in type 2 diabetes mellitus took part in the research. All patients received standard treatment using angioprotectors and antioxidants. Additionally, correctors of dyslipidemia were prescribed – statins (atorvastatin 20 mg per a day) and fibrates (lipofen 250 mg per a day) – to 21 of the patients. The quantity of microaneurysms, hemorrhages, hard and soft exudates, areas of macular edema were determined by perimetry, optical coherence tomography (OCT), and fluorescein angiography (FA). The patients were observed for 1 year. Results: After using statins and fibrates, macular disease (MD) decreased from −3.5 to −4.5 dB, and in the control group (without using correctors of dyslipidemia) it increased from −3.7 to −8.1 dB (p < 0.01). The quantity of local defects in visual fields in both research groups increased from 11.9 to 16.5 points, but increased significantly in the control group from 12.3 to 20.6 points (p < 0.01) compared with the treated group. On FA and OCT there were more intraretinal hemorrhages and hard exudates in control patients than in the research group. Conclusions: Correctors of dyslipidemia are useful for patients with nonproliferative diabetic retinopathy in type 2 diabetes mellitus. The treatment slows down the progression of diabetic retinopathy. © 2016, Springer-Verlag Wien.
引用
收藏
页码:111 / 116
页数:5
相关论文
共 50 条
  • [1] Metabolic control and diabetic retinopathy in patients with diabetes type 2; [Stoffwechselkontrolle und diabetische Retinopathie bei Patienten mit Typ-2-Diabetes]
    Kosanović-Jaković N.
    Resan M.
    Dimitrijević-Srećković V.
    Vukosavljević M.
    Milenković S.
    Čolak E.
    Risović D.
    Avramović S.
    Canović F.
    Spektrum der Augenheilkunde, 2010, 24 (3) : 157 - 161
  • [2] Bewegung als Therapie bei Diabetes mellitus Typ 2Physical exercise as treatment of type 2 diabetes mellitus
    D. König
    A. Berg
    Der Internist, 2012, 53 : 678 - 687
  • [3] „Bewegung als Medikament“ in der Therapie des Typ-2-Diabetes“Physical activity as medicine” in the treatment of type 2 diabetes
    M. Kemper
    M. Halle
    Der Diabetologe, 2011, 7 : 15 - 20
  • [4] Type-2-diabetes in children and adolescents [Typ-2-diabetes mellitus bei kindern und jugendlichen]
    Holl R.W.
    Wabitsch M.
    Heinze E.
    Monatsschrift Kinderheilkunde, 2001, 149 (7) : 660 - 669
  • [6] Formuladiets for treatment of type 2 diabetes [Formuladiäten bei der behandlung des typ-2-diabetes]
    Martin S.
    Kempf K.
    Der Diabetologe, 2014, 10 (2): : 122 - 129
  • [7] Wirksamkeit der Inkretin-Therapie bei Typ-2-Diabetes – eine Metaanalyse
    B. Rose
    Der Diabetologe, 2008, 4 : 125 - 126
  • [8] Conventional and combined insulin treatment in type 2 diabetes [Konventionelle und kombinierte insulintherapie bei typ-2-diabetes]
    Janka H.U.
    Der Diabetologe, 2006, 2 (4): : 304 - 313
  • [9] Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2Lipids: diagnosis and therapy in type 2 diabetes
    Thomas C. Wascher
    Bernhard Paulweber
    Hermann Toplak
    Christoph Saely
    Heinz Drexel
    Wiener klinische Wochenschrift, 2012, 124 (Suppl 2) : 28 - 30
  • [10] GLP-1-Analoga in der Therapie des Typ-2-Diabetes bei JugendlichenGLP-1 analogues for treatment of type 2 diabetes in adolescents
    Caroline Veyder-Malberg
    Dieter Furthner
    Christopher Dalus
    Katharina Maruszczak
    Anna-Maria Schneider
    Daniel Weghuber
    Monatsschrift Kinderheilkunde, 2021, 169 (3) : 253 - 257